Basics pp 19-27 | Cite as

Off-Label Drugs in Pediatric Perioperative Medicine

  • Marinella Astuto
  • Manuela Antoci
  • Antonino Gullo
Part of the Anaesthesia, Intensive Care and Pain in Neonates and Children book series (AICPNC)


The drug licensing system was introduced with the aim of ensuring that medicines are marketed only after having been examined for safety, efficacy and quality. So, before a drug is allowed on the market, a favorable balance between beneficial and harmful effects has to be demonstrated. Often this has been established only in adults and once a drug is approved, it may be prescribed by a physician for any population or disease state desired. Many drugs pass through the licensing process without being evaluated in children. The product license often contains statements such as “not recommended for use in children” or “no evidence for use in children.” This usually reflects an absence of data in children rather than a specific reason for the drug not to be used.


Pediatric Intensive Care Unit Paediatric Ward Product License License Drug Pediatric Clinical Trial 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Gazarian M, Kelly M, McPhee JR et al (2006) Off-label use of medicines: consensus recommendations for evaluating appropriateness. Med J Aust 185:544–548PubMedGoogle Scholar
  2. 2.
    Schirm E, Tobi H, de Jong-van den Berg LT (2003) Risk factors for unlicensed and off-label drug use in children outside the hospital. Pediatrics 111:291–295CrossRefPubMedGoogle Scholar
  3. 3.
    Beck JM, Azari ED (1998) FDA, off-label use, and informed consent: debunking, myths and misconception. Food Drug Law J 53:71–104PubMedGoogle Scholar
  4. 4.
    Novak E, Allen PJ (2007) Prescribing medications in pediatrics: concerns regarding FDA approval and pharmacokinetics. Pediatr Nurs 33:64–70PubMedGoogle Scholar
  5. 5.
    Dunne J (2007) The European Regulation on medicines for paediatric use. Paediatric Respir Rev 8:177–183CrossRefGoogle Scholar
  6. 6.
    Poetsch J (2006) Legal issues in the off-label use of drug medication in paediatrics. J Dtsch Dermatol Ges 4:421–426CrossRefPubMedGoogle Scholar
  7. 7.
    Lifshitz M, Gavrilov V, Gorodischer R (2001) Off-label and unlicensed use of antidotes in paediatric patients. Eur J Clin Pharmacol 56:839–841CrossRefPubMedGoogle Scholar
  8. 8.
    Conroy S, McIntyre J, Choonara I, Stephenson T (2000) Drugs trials in children: problems and the way forward. Br J Clin Pharmacol 49:93–97CrossRefPubMedGoogle Scholar
  9. 9.
    Cuzzolin L, Zaccaron A, Fanos V (2003) Unlicensed and off-label uses of drugs in paediatrics: a review of the literature. Fundam Clin Pharmacol 17:125–131CrossRefPubMedGoogle Scholar
  10. 10.
    Conroy S, Choonara I, Impicciatore P et al (2000) Survey on unlicensed and off-label drug use in paediatric wards in European countries. BMJ 320:79–82CrossRefPubMedGoogle Scholar
  11. 11.
    Pandolfini C, Bonati M (2005) A literature review on off-label drug use in children. Eur J Pediatr 164:552–558CrossRefPubMedGoogle Scholar
  12. 12.
    Caron S, Choonara I, Impicciatore P (2000) Survey on unlicensed and off-label drug use in paediatric wards in European countries. BMJ 320:79–82CrossRefGoogle Scholar
  13. 13.
    Bennet WM (2004) Off-label use of approved drugs: therapeutic opportunity and challenges. J Am Soc Nephrol 15:830–831CrossRefGoogle Scholar
  14. 14.
    Choonara I (2004) Unlicensed and off-label drug use in children: implications for safety. Expert Opin Drug Saf 3:81–83CrossRefPubMedGoogle Scholar
  15. 15.
    Cuzzolin L, Atzei A, Fanos V (2006) Off-label and unlicensed prescribing for newborns and children in different settings: a review of the literature and a consideration about drug safety. Expert Opin Drug Saf 5:703–718CrossRefPubMedGoogle Scholar
  16. 16.
    Neubert A, Dormann H, Weiss J et al (2004) The impact of unlicensed and off label drug use on adverse drug reactions in paediatric patients. Drug Saf 27:1059–1067CrossRefPubMedGoogle Scholar
  17. 17.
    Dell’Aera M, Gasbarro AR, Padovano M (2007) Unlicensed and off-label use of medicines at a neonatology clinic in Italy. Pharm World Sci 29:361–367CrossRefPubMedGoogle Scholar
  18. 18.
    American Society of Oncology (2006) Reimbursement for cancer treatment: coverage of off-label drug indications. J Clin Oncol 24:3206–3208CrossRefGoogle Scholar
  19. 19.
    Shah SS, Hall M, Goodman DM et al (2007) Off-label drug use in hospitalized children. Arch Pediatr Adolesc Med 161:282–290CrossRefPubMedGoogle Scholar
  20. 20.
    Jong GW, Eland IA, Sturkenboom MC et al (2004) Unlicensed and off-label prescription of respiratory drugs to children. Eur Respir J 23:310–313CrossRefPubMedGoogle Scholar
  21. 21.
    Bajetic M, Jelisavcic M, Mitrovic J et al (2005) Off-label and unlicensed drugs use in paediatric cardiology. Eur J Clin Pharmacol 61:775–779CrossRefGoogle Scholar
  22. 22.
    Turner S, Longworth A, Ninn AJ, Choonara I (1998) Unlicensed and off-label drug use in paediatric wards: prospective study. BMJ 316:343–345PubMedGoogle Scholar
  23. 23.
    Choonara I, Conroy S (2002) Unlicensed and off-label drug use in children: implications for safety. Drug Saf 25:1–5CrossRefPubMedGoogle Scholar
  24. 24.
    Turner S, Nunn AJ, Fielding K, Choonara I (1999) Adverse drug reactions to unlicensed and off-label drugs on paediatric wards: a prospective study. Acta Paediatr 88:965–968CrossRefPubMedGoogle Scholar
  25. 25.
    Turner S, Gill A, Nunn T et al (1996) Use of “off-label” and unlicensed drugs in paediatric intensive care unit. Lancet 347:549–550CrossRefPubMedGoogle Scholar
  26. 26.
    Conroy S, McIntyre J, Choonara I (1999) Unlicensed and off label drug use in neonates. Arch Dis Child Fetal Neonatal Ed. 80:F142–4; discussion F144-145CrossRefPubMedGoogle Scholar
  27. 27.
    Wilton LV, Pearce G, Mann RD (1999) The use of newly marketed drugs in children and adolescents prescribed in general practice. Pharmacoepidemiol Drug Saf 8Suppl 1:S37–45CrossRefPubMedGoogle Scholar
  28. 28.
    ’t Jong GW, Vulto AG, de Hoog M et al (2000) Unapproved and off-label use of drugs in a children’s hospital. N Engl J Med 343:1125CrossRefPubMedGoogle Scholar
  29. 29.
    Gavrilov V, Lifshitz M, Levy J, Gorodischer R (2000) Unlicensed and off-label medication use in a general pediatrics ambulatory hospital unit in Israel. Isr Med Assoc J 2:595–597PubMedGoogle Scholar
  30. 30.
    Chalumeau M, Tréluyer JM, Salanave B et al (2000) Off label and unlicensed drug use among French office based paediatricians. Arch Dis Child 83:502–505CrossRefPubMedGoogle Scholar
  31. 31.
    McIntyre J, Conroy S, Avery A et al (2000) Unlicensed and off label prescribing of drugs in general practice. Arch Dis Child 83:498–501CrossRefPubMedGoogle Scholar
  32. 32.
    Craig JS, Henderson CR, Magee FA (2001) The extent of unlicensed and off-label drug use in the paediatric ward of a district general hospital in Northern Ireland. Ir Med J 94:237–240PubMedGoogle Scholar
  33. 33.
    ’t Jong GW, Vulto AG, de Hoog M et al (2001) A survey of the use of off-label and unlicensed drugs in a Dutch children’s hospital. Pediatrics 108:1089–1093CrossRefPubMedGoogle Scholar
  34. 34.
    Pandolfini C, Impicciatore P, Provasi D et al; Italian Paediatric Off-label Collaborative Group (2002) Off-label use of drugs in Italy: a prospective, observational and multicentre study. Acta Paediatr 91:339–347CrossRefPubMedGoogle Scholar
  35. 35.
    O’Donnell CP, Stone RJ, Morley CJ (2002) Unlicensed and off-label drug use in an Australian neonatal intensive care unit. Pediatrics 110:e52CrossRefPubMedGoogle Scholar
  36. 36.
    ’t Jong GW, van der Linden PD, Bakker EM (2002) Unlicensed and off-label drug use in a paediatric ward of a general hospital in the Netherlands. Eur J Clin Pharmacol 58:293–297. Epub 2002 Jun 15CrossRefPubMedGoogle Scholar
  37. 37.
    Bücheler R, Schwab M, Mörike K et al (2002) Off label prescribing to children in primary care in Germany: retrospective cohort study. BMJ 324:1311–1312CrossRefPubMedGoogle Scholar
  38. 38.
    Carvalho PR, Carvalho CG, Alievi PT et al (2003) Prescription of drugs not appropriate for children in a Pediatric Intensive Care Unit. J Pediatr (Rio J) 79:397–402Google Scholar
  39. 39.
    Schirm E, Tobi H, de Vries TW et al (2003) Lack of appropriate formulations of medicines for children in the community. Acta Paediatr 92:1486–1489CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Italia 2009

Authors and Affiliations

  • Marinella Astuto
    • 1
  • Manuela Antoci
    • 2
  • Antonino Gullo
    • 1
  1. 1.Department of Anesthesia and Intensive Care, Pediatric Anesthesia and Intensive Care SectionCatania University HospitalCataniaItaly
  2. 2.Department of Anesthesia and Intensive Care, Postgraduate School of Anesthesia and Intensive CareCatania University HospitalCataniaItaly

Personalised recommendations